# **ONLINE SUPPLEMENTAL MATERIAL**

## **ONLINE SUPPLEMENTAL METHODS**

## qRT-PCR

RNA from hCMEC/D3 were extracted using the Nucleospin RNA (Macherey-Nagel) and quantified using the NanoDrop ND-100 (ThermoFisher). cDNA synthesis was performed from 1  $\mu$ g of RNA using oligo-dT (ThermoFisher) and SuperScript IV RT (ThermoFisher). RT-qPCR was performed using Power SYBR Green PCR system (ThermoFisher) and specific primers (listed in Supplemental Table 3) on the LightCycler 480 Real-Time PCR System (Roche). Results were normalized using 18S as the housekeeping gene and expressed as mean fold change relative to uninfected condition  $\pm$  SEM. Statistical analysis: One-Way Anova, with NS, non-significant; \*, p < 0.05.

### **ONLINE SUPPLEMENTAL TABLES AND FIGURES**

TABLE S1: Bacterial strains used in this study

| Characteristics  | Reference  |
|--|--|
| CC17 isolate from neonate blood culture (serotype III)         | (15)   |
| CC23 isolated from neonate blood culture (serotype III)        | (15)   |
| BM110 deleted in srr2 gene                                     | (6)  |
| BM110 $\Delta srr2$ complemented with pAT28-BR <sub>Srr2</sub> | (16)   |
| BM110 \(\Delta srr2\) complemented with pAT28 empty vector     | (16)   |
|  | This study   |
|  | CC17 isolate from neonate blood culture (serotype III)  CC23 isolated from neonate blood culture (serotype III)  BM110 deleted in <i>srr2</i> gene  BM110 Δ <i>srr2</i> complemented with pAT28-BR <sub>Srr2</sub> |

TABLE S2: Plasmids used in this study

| Plasmids          | Vectors | insert                         | reference       |
|-------------------|---------|--------------------------------|-----------------|
| pET-BR2           | pET2818 | BR <sub>Srr2</sub>             | (16)            |
| pET-BR2-RGD*      | pET2818 | BR <sub>Srr2</sub> RGD:AAA     | This study      |
| pET-BR2-SDV*      | pET2818 | BR <sub>Srr2</sub> SDV:AAA     | This study      |
| pET-BR2-RGD*-SDV* | pET2818 | BR <sub>Srr2</sub>             | This study      |
|                   |         | RGA:AAA;SDV:AAA                |                 |
| pET-BR2-FSVKI*    | pET2818 | BR <sub>Srr2</sub> FSVKI:FAAAI | This study      |
| pET-BR2-ETYVI*    | pET2818 | BR <sub>Srr2</sub> ETYVI:AAYAI | This study      |
| pGU2664           |         | GFP                            | Sullivan et al. |

# SUPPLEMENTARY REFERENCE

Sullivan MJ, and Ulett GC. Stable Expression of Modified Green Fluorescent Protein in Group B Streptococci To Enable Visualization in Experimental Systems. *Appl Environ Microbiol.* 2018;84(18).

TABLE S3: Primers used in this study


| Primers       | Sequence (5'-3')  |  |  |
|---------------|---|--|--|
| RGD:AAA-F     | cactattgattctgtgaatgcagctgctacttttgaaattaagttatc                            |  |  |
| RGD:AAA-R     | gataacttaatttcaaaagtagcagctgcattcacagaatcaatagtg                            |  |  |
| SDV:AAA-F     | gatgatgatgggatccagcattagcagctgcatatcccgatccagatgagtaagt                     |  |  |
| SDV:AAA-R     | acttactcatctggatcgggatatgcagctgctaatgctggatcccatcatcatc                     |  |  |
| FSVKI-FAAAI-F | acagttcaaaacacaaaagaagatgttctttttgcggcagcaataaaggatcaagaggctacaatt aaagaaac |  |  |
| FSVKI-FAAAI-R | gtttctttaattgtagcctcttgatcctttattgctgccgcaaaaagaacatcttcttttgtgttttgaactgt  |  |  |
| ETYVI-AAYAI-F | gggggcagtttattgcatcaaatgcagcgtatgcaattgttgtagaaacaccatttac                  |  |  |
| ETYVI-AAYAI-R | gtaaatggtgtttctacaacaattgcatacgctgcatttgatgcaataaactgccccc                  |  |  |
| q-PCR-α5-F    | aatcttattaccccgagtacc   |  |  |
| q-PCR-α5-R    | tatcctaggtagctgtcatc  |  |  |
| q-PCR-β3-F    | ctccggccagatgattc   |  |  |
| q-PCR-β3-R    | tcctccatggagtaagacag  |  |  |

Mutagenized motifs of interest are indicated in red letters.

TABLE S4: Antibodies used in this study

| target         | clone        | supplier               | use                      |
|----------------|--------------|------------------------|--------------------------|
| Anti-Srr2      |              | Laboratory stock (16)  | Dot-Blot/inhibition      |
| Anti-Srr1      |              | S. Dramsi              | Dot-Blot                 |
| Anti-GBS       | PA1-7250     | Thermofisher           | Counter-staining         |
| Anti-ZO1       | 339100       | Thermofisher           | IF                       |
| Anti-ICAM1     | Ab2213       | Abcam                  | ELISA                    |
| Anti-β1        | AIIB2/P5D2   | DSHB                   | ELISA (human integrin)   |
| Anti-ανβ3      | LM609        | Millipore              | ELISA (human integrin)   |
| Anti-β1        | Mab1997      | Chemicon international | ELISA (mouse integrin)   |
| Anti-β3        | MAB41182     | R&D                    | ELISA (mouse integrin)   |
| Anti-α5        | Ab150361     | Abcam                  | IF, WB, IHC              |
| Anti-β3        | sc-19671-L   | Santa Cruz             | IF                       |
| Anti-β3        | 4702         | Cell signalling        | WB                       |
| Anti-β3        | 13166        | Cell signalling        | IHC                      |
| Anti-α5        | MFR5 5H10-27 | BD pharmingen          | Blocking in vivo         |
| Isotype contro | 16-4321-85   | Invitrogen             | Control blocking in vivo |
| Anti-CD31      |              | BD pharmingen          | IHC                      |
| Anti-TTR       |              | Abcam                  | IHC                      |

The AIIB2 and P5D2 antibodies were developed by Damsky, C.H. and Wayner, E.A., respectively and obtained from the Developmental Studies Hybridoma Bank (DSHB), created by the NICHD of the NIH and maintained at The University of Iowa, Department of Biology, Iowa City, IA 52242.



**Figure S1: Purification of BR**<sub>Srr2</sub> and **BR**<sub>Srr1</sub> forms. (A) BR<sub>Srr1</sub> and BR<sub>Srr2</sub> were purified and analyzed by Coomassie staining. (B and C) RGD and/or SDV motifs were mutagenized. Resulting proteins were purified and analyzed by (B) Coomassie staining (C) or Western Blot analysis using an anti-Srr2 antibody; lane 1, Native BR<sub>Srr2</sub>; 2, RGD:AAA; 3, SDV:AAA; 4, RGD:AAA + SDV:AAA. (D and E) FSVKI or ETYVI motifs were mutagenized. Resulting proteins were purified and analyzed by (D) Coomassie staining (E) or Western Blot analysis using an anti-Srr2 antibody; lane 1, Native BR<sub>Srr2</sub>; 2, FSVKI:FAAAI; 3, ETYVI:AAYVI.




Figure S2: Influence of divalent cations on the interaction of BR<sub>Srr2</sub> with  $\alpha$ 5 $\beta$ 1 or  $\alpha$ v $\beta$ 3 integrins. Interaction of BR<sub>Srr2</sub> with (A)  $\alpha$ 5 $\beta$ 1 or (B)  $\alpha$ v $\beta$ 3 integrin was assessed by ELISA in the absence of divalent cations (black) or in the presence of 1mM of CaCl<sub>2</sub> (green) or 1mM of MnCl<sub>2</sub> (red). Results were normalized to the negative control (BSA). Error bars *correspond* to SEM of three independent experiments. Two-Way ANOVA statistical analysis between divalent cations treatments or absence of treatment was performed with NS, non-significant; \*, p < 0.05; \*\*\*, p < 0.01; \*\*\*\*, p < 0.001.





Figure S3: BR<sub>Srr1</sub> and BR<sub>Srr2</sub> recognize other integrins. Interaction of BR<sub>Srr2</sub> (black) and BR<sub>Srr1</sub> (grey) with integrin (A)  $\alpha6\beta1$ , (B)  $\alpha4\beta1$ , (C)  $\alpha3\beta1$ , or (D)  $\alpha1\beta1$  was assessed by ELISA. Results were normalized to negative control (BSA). Error bars correspond to SEM of three independent experiments.

Α






Figure S4:  $\alpha$ 5β1 integrin binding motif on BR<sub>Srr2</sub>. (A) *In silico* predicted contacts between BR<sub>Srr2</sub> (PDB code: 4MBR) and  $\alpha$ 5β1Integrin (PDB code: 4WJK) using the RaptorX Protein Complex Contact Prediction server (http://raptorx.uchicago.edu/ComplexContact/). Residues of BR<sub>Srr2</sub> and  $\alpha$ 5β1 integrin predicted as involved in the interactions are given on the x and y-axis, respectively. The probability values were thresholded at 0.7 to highlight relevant contact clusters. (B) Structure of BR<sub>Srr2</sub> showing that both  $\alpha$ vβ3 binding motifs: RGD (blue) and SDV (red) are localized on the same side of BR<sub>Srr2</sub>, while  $\alpha$ 5β1 binding motif, FSVKI (green) is located on the opposite side.




Figure S5: Infection of hCMEC/D3 by CC17 strain does not affect integrin expression. (A and C) q-RT-PCR data analyzing fold change of (A)  $\alpha$ 5 subunit integrin or (C)  $\beta$ 3 subunit integrin following hCMEC/D3 infection with CC17 strain for 1 or 3 h. Results are expressed as mean  $\pm$  SEM of at least 3 independent experiments in duplicate. Statistical analysis: One-Way ANOVA with NS, non-significant. (**B and D**) Changes in protein levels assessed by Western Blot analysis of (B)  $\alpha$ 5 or (D)  $\beta$ 3 integrin subunit, in hCMEC/D3 after 1 or 3 h of infection with CC17 strain.






Figure S6: BR<sub>Srr2</sub> recognize  $\alpha 5\beta 1$  and  $\alpha \nu \beta 3$  mouse integrins. Interaction of BR<sub>Srr2</sub> with mouse (A)  $\alpha 5\beta 1$ , or (B)  $\alpha \nu \beta 3$  integrins were assessed by ELISA. Results were normalized to negative control (BSA). Error bars *correspond* to SEM of three to five independent experiments.